http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CY-1120838-T1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a693232b92910547c898db10feb83fef |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 |
| filingDate | 2018-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a45b367ab38f65254953ef62dea3f4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ecc3400fb3c326726ea8c9459421423 |
| publicationDate | 2019-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CY-1120838-T1 |
| titleOfInvention | METHOD OF ADMINISTRATION 4 - ((1R, 3S) -6-XLOPO-3-PHINYLO-INDAN-1-YLO) |
| abstract | The present invention relates to 4 - ((1R, 3S) -6-chloro-3-phenyl-indan-1-yl) -1,2,2-trimethyl-piperazine and its salts acting on dopamine D1 and D2 receptors as well as the serotonin 5HT2 receptor for central nervous system disease in a once-weekly dosing regimen. |
| priorityDate | 2011-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419592315 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11465618 |
Total number of triples: 14.